News

News

May 30, 2023
AnaptysBio Announces Participation in Upcoming Investor Conferences
SAN DIEGO , May 30, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga , interim president and chief executive officer of AnaptysBio , and other members of its
April 6, 2023
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
SAN DIEGO , April 06, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the appointment of Rita Jain , M.D., to the company’s Board of Directors, effective immediately.
March 27, 2023
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent
Results published in The   New England Journal of Medicine and presented simultaneously at ESMO Virtual Plenary and SGO Annual Meeting 72% and 36% reduction in the risk of disease progression or death observed in the dMMR/MSI-H population and overall patient population, respectively Clinically
January 13, 2023
AnaptysBio Announces Stock Repurchase Plan
SAN DIEGO , Jan. 13, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase